Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report released on Friday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their target price on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Evogene Stock Performance

Shares of EVGN opened at $2.43 on Friday. The firm has a market cap of $100.15 million, a P/E ratio of -5.28 and a beta of 1.40. Evogene has a twelve month low of $2.14 and a twelve month high of $10.40. The firm’s 50 day moving average price is $2.93 and its two-hundred day moving average price is $5.14.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.